Hemophilia Drugs Market to Reach USD 15,830.3 Million at 6.0% CAGR Forecast by 2026

 A worldwide emphasis on hemophilia cases is mainly due to the fact that an exceptional amount of blood is lost in people diagnosed with Hemophilia. Hemophilia treatments are prioritized by healthcare institutions around the world, and rising cases of hemophilia has created an increasing need for efficient treatments. Along with high prevalence of Hemophilia, a relatively low survival rate is boosting the Hemophilia Drugs Market. According to a report published by Fortune Business Insights titled, ‘Hemophilia Drugs: Global Market Analysis, Insights and Forecasts, 2019-2026, the market was valued at US$ 9,875.4 Mn in 2018. Furthermore, recent advancements in hemophilia drugs and increasing clinical trials are major indications of an increased market value, estimated to be around US$ 15,830.3 Mn by the end of 2026.

With a strong market portfolio, Takeda Pharmaceutical Company Limited has emerged as the leading player in the global hemophilia drugs market. With recent acquisition of Shire PLC, Takeda is estimated to retain its position in the forecast period. The company has further adopted efficient business expansion strategies across numerous countries. Together with F. Hoffmann-La Roche Ltd and Novo Nordisk, Takeda Pharmaceutical Company Limited accounted for more than half of the market share in terms of revenue in 2018.

Hemophilia-A to Emerge as leading Disease Indication Segment 

Hemophilia-A has the highest prevalence of diseases within the global population, among all three diseases indications. It was found that the annual cost of care within hospitalization and medications for hemophilia-A treatments is exceptionally high. As of 2018, Hemophilia-A single handedly accounted for almost 85% of the total market share. Moreover, approvals from regulatory authorities towards brands such as Humira and other drugs for treatment of Hemophilia-A is a major reason why this segment may continue to dominate the segment during the forecast period. 

Recombinant Therapy Type to Emerge as Leading Segment 

The recombinant therapy accounted for the maximum market share in 2018, owing to improved outcome of recombinant therapeutics over the plasma-derived therapy. Having said that, other therapies such as gene therapy and biospecific drugs is likely to grow at a higher rate during the forecast period. 

Browse Complete Reports Details:https://www.fortunebusinessinsights.com/industry-reports/hemophilia-drugs-market-100068

Healthy Market Competition Is Favoring the Hemophilia Drugs Market in North America 

North America accounted for the maximum share in the global hemophilia drugs market. As of 2018, the hemophilia drugs market in North America was valued at US$ 3,684.7 Mn. Exceptional business strategies adopted by leading pharmaceutical companies in the U.S. is boosting the hemophilia drugs market in North America. Furthermore, increasing cases of hemophilia A & B in the U.S. are favoring numerous clinical trials of hemophilia drugs in the U.S. On account of the aforementioned factors, North America will retain its dominance during the period of 2019-2026. 

Despite North America’s dominance, Asia Pacific is likely to grow at the highest CAGR during the forecast period. This is mainly attributable to the increase in regulatory approvals of clinical drugs in Australia and Japan hemophilia-A treatments. Moreover, increased funding and investment by public organizations as well as private companies aimed at development of healthcare facilities in India and China boosting the hemophilia drugs market in Asia Pacific.

The Global Hemophilia Treatments market is segmented based on: